Familial CD45RA^- T cells to treat severe refractory infections in immunocompromised patients.

ABSTRACT:

Background

Immunocompromised patients are susceptible to high-risk opportunistic infections and malignant diseases. Most antiviral and antifungal drugs are quite toxic, relatively ineffective, and induce resistance in the long term. The transfer of pathogen-specific Cytotoxic T-Lymphocytes has shown a minimal toxicity profile and effectiveness in treating Cytomegalovirus, Adenovirus, Epstein - Barr virus, BK Virus and Aspergillus infections, but this therapy have the main limitations of regulatory issues, high cost, and absence of public cell banks. However, CD45RA^- cells containing pathogen-specific memory T-cells involve a less complex manufacturing and regulatory process and are cheaper, feasible, safe, and potentially effective.

Methods

We present preli

SUBMITTER: Al-Akioui Sanz K 

PROVIDER: S-EPMC9944023 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature